• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Falls 150 Points; US Economy Adds 353,000 Jobs In January

    2/2/24 9:48:35 AM ET
    $CING
    $GRI
    $INBS
    $MARK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CING alert in real time by email

    U.S. stocks traded mixed this morning, with the Dow Jones index falling around 150 points on Friday.

    Following the market opening Friday, the Dow traded down 0.39% to 38,370.46 while the NASDAQ rose 0.56% to 15,447.53. The S&P 500 also rose, gaining, 0.18% to 4,914.99.

    Check This Out: Amazon To Rally Over 41%? Here Are 10 Top Analyst Forecasts For Friday

     

    Leading and Lagging Sectors

     

    Communication services shares rose by 2.9% on Friday.

    In trading on Friday, real estate shares fell by 2%.

     

    Top Headline

     

    U.S. non-farm payrolls increased by 353,000 in January, a jump from the upwardly revised figure of 333,000 for December and well above the expected 180,000.

    The unemployment rate remained steady at 3.7%, below the expected 3.8%.

     

    Equities Trading UP

     

    Intelligent Bio Solutions Inc. (NASDAQ:INBS) shares shot up 90% to $4.57.
    Intelligent Bio Solutions said it sees preliminary second-quarter revenue of $0.76 million.

    Shares of Minim, Inc. (NASDAQ:MINM) got a boost, surging 45% to $7.30 after gaining more than 22% on Thursday.

    Remark Holdings, Inc. (NASDAQ:MARK) shares were also up, gaining 27% to $0.6499.

     

    Equities Trading DOWN

     

    Cingulate Inc. (NASDAQ:CING) shares dropped 44% to $1.87. Cingulate announced pricing of $7.5 million public offering of 3.750 million shares at $2.00 per share.

    Shares of MedAvail Holdings, Inc. (NASDAQ:MDVL) were down 44% to $1.75.

    GRI Bio, Inc. (NASDAQ:GRI) was down, falling 25% to $1.46 after the company announced pricing of $5.5 million public offering.

    Also Check This Out: Top 4 Health Care Stocks That May Crash This Quarter

     

    Commodities

     

    In commodity news, oil traded down 0.5% to $73.45 while gold traded down 1% at $2,051.00.

    Silver traded down 2.2% to $22.725 on Friday while copper fell 0.7% to $3.8275.

     

    Euro zone

     

    European shares were higher today. The eurozone’s STOXX 600 gained 0.5%, London’s FTSE 100 rose 0.4% while Spain’s IBEX 35 Index rose 0.7% The German DAX rose 0.7% French CAC 40 rose 0.4% while Italy’s FTSE MIB Index rose 0.5%.

    Industrial production in France rose 1.1% month-over-month in December following a 0.5% increase in the prior period. The number of foreign tourist arrivals in Spain surged by 26.2% year-over-year to 5.2 million in December.

     

    Asia Pacific Markets

     

    Asian markets closed mixed on Friday, with Japan’s Nikkei 225 gaining 0.41%, Hong Kong’s Hang Seng Index falling 0.21% and China’s Shanghai Composite Index falling 1.46%. India’s S&P BSE Sensex, meanwhile, rose 0.61%.

    Australian final demand producer price index rose by 0.9% quarter-over-quarter in the fourth quarter, versus a 1.8% rise in the third quarter.

     

    Economics

     

    Non-farm payrolls increased by 353,000 in January, a jump from the upwardly revised figure of 333,000 for December and well above the expected 180,000.

    The unemployment rate remained steady at 3.7%, below the expected 3.8%.

    Average hourly earnings showed 0.6% growth for the month, a sharp increase from the previous 0.4% and below the predicted 0.3%.

    Now Read This: DoorDash, KB Home And 2 Other Stocks Insiders Are Selling

    Get the next $CING alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CING
    $GRI
    $INBS
    $MARK

    CompanyDatePrice TargetRatingAnalyst
    Cingulate Inc.
    $CING
    1/10/2025$12.00Buy
    ROTH MKM
    GRI Bio Inc.
    $GRI
    12/9/2024$10.00Buy
    H.C. Wainwright
    Cingulate Inc.
    $CING
    12/22/2023Buy → Hold
    Laidlaw
    Cingulate Inc.
    $CING
    1/20/2022$8.50Buy
    Laidlaw & Co.
    Cingulate Inc.
    $CING
    1/11/2022$9.00Buy
    Aegis Capital
    Minim Inc.
    $MINM
    10/25/2021$3.00Outperform
    Northland Capital Markets
    Minim Inc.
    $MINM
    8/6/2021$4.00Buy
    B. Riley Securities
    More analyst ratings

    $CING
    $GRI
    $INBS
    $MARK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP and CFO Callahan Jennifer L. bought $24,515 worth of shares (4,864 units at $5.04), increasing direct ownership by 2,494% to 5,059 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Schaffer Shane J. bought $34,317 worth of shares (6,809 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:19 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Werth Peter J. bought $98,053 worth of shares (19,455 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    $GRI
    $INBS
    $MARK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Intelligent Bio Solutions Successfully Manufactures and Ships First Readers with New Partner, Accelerating Scale and Driving Gross Margin Expansion in Anticipation of Planned U.S. Entry

    Successful delivery in partnership with Syrma Johari validates manufacturing scale, strengthens commercial readiness, and supports planned U.S. market entry in 2026 Partnership on track to deliver annual production cost savings of more than 40% with expected improvement of approximately 20 percentage points in gross margin annually Doubled in-house lateral flow test strip production capacity strengthens vertical integration, accelerates R&D, and enables panel expansion NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today a

    2/25/26 8:45:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Partners with Bouygues UK, Part of Multi-Billion Dollar Global Construction Giant Bouygues Construction, for UK Drug Testing Rollout

    NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a partnership with Bouygues UK, a subsidiary of Bouygues Construction, a multi-billion-dollar global construction firm with 35,600 employees, for the deployment of INBS's fingerprint drug screening technology across its UK operations. The partnership reflects a shift from third-party testing services to an in-house solution, driven by superior hygiene protocols, operational efficiency, and demonstrated cost savings, validated through joint Return on Investment ("ROI") a

    2/24/26 8:45:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules

    KANSAS CITY, Kan., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company advancing next-generation treatments for ADHD and other CNS disorders, today announced the successful closing of a $12 million private investment in public equity (PIPE) financing, led by certain affiliates of Falcon Creek Capital Advisor LLC ("Falcon Creek Capital"). "This long-term financing from life science–focused institutional investors represents strong validation of our strategy, our technology, and the significant commercial opportunity ahead. The transaction included insider participation underscoring our confidence in the value we are building and our commitment to sta

    2/17/26 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    $GRI
    $INBS
    $MARK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Cingulate with a new price target

    ROTH MKM initiated coverage of Cingulate with a rating of Buy and set a new price target of $12.00

    1/10/25 7:39:52 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on GRI Bio with a new price target

    H.C. Wainwright initiated coverage of GRI Bio with a rating of Buy and set a new price target of $10.00

    12/9/24 7:50:37 AM ET
    $GRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate downgraded by Laidlaw

    Laidlaw downgraded Cingulate from Buy to Hold

    12/22/23 7:22:08 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    $GRI
    $INBS
    $MARK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP and CFO Callahan Jennifer L. bought $24,515 worth of shares (4,864 units at $5.04), increasing direct ownership by 2,494% to 5,059 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Schaffer Shane J. bought $34,317 worth of shares (6,809 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:19 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Werth Peter J. bought $98,053 worth of shares (19,455 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    $GRI
    $INBS
    $MARK
    SEC Filings

    View All

    SEC Form DEF 14A filed by Cingulate Inc.

    DEF 14A - Cingulate Inc. (0001862150) (Filer)

    3/2/26 7:00:33 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intelligent Bio Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

    2/25/26 9:15:25 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    SEC Form PRE 14A filed by Cingulate Inc.

    PRE 14A - Cingulate Inc. (0001862150) (Filer)

    2/18/26 4:05:55 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    $GRI
    $INBS
    $MARK
    Leadership Updates

    Live Leadership Updates

    View All

    Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Industry Veteran Bryan Downey Named Chief Commercial Officer NDA Accepted with May 2026 PDUFA Date Commercial Supply Agreement Executed KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to build a pipeline of next-generation products, today announced financial results for the quarter ended September 30, 2025, and provided recent corporate highlights. Recent Highlights (Post-Q3) FDA Accepts NDA for CTx-1301; PDUFA Date Set for May 31, 2026In October of 2025, the U.S. Food and Drug Administration (FDA) accepted Cingulate's New Drug Application

    11/13/25 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301

    Appointment builds on recent FDA acceptance of New Drug Application for review and advances Cingulate's transition toward commercialization pending FDA approval Company also strengthens its cash position by completing a $6 million financing KANSAS CITY, Kan., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™) drug-delivery platform, today announced the appointment of Bryan Downey as Chief Commercial Officer, following the U.S. Food and Drug Administration's (FDA) acceptance of Cingulate's New Drug Application (ND

    11/10/25 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application

    KANSAS CITY, Kan., July 09, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, has named Nilay Patel, JD, as Chief Legal Officer. Patel's appointment comes as Cingulate plans to submit a new drug application to the FDA in coming weeks for its lead asset CTx-1301 (dexmethylphenidate HCl) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Mr. Patel brings more than two decades of legal and compliance leadership in the pharmaceutical industry, having advised companies across

    7/9/25 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    $GRI
    $INBS
    $MARK
    Financials

    Live finance-specific insights

    View All

    Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year

    First half fiscal 2026 revenue surpasses $2 million, up 36% year-over-year  Reader sales more than double to 104% year-over-year for the second quarter, demonstrating razor-razorblade model momentum Gross profit margins for first half fiscal 2026 increased 10% year-over-year to 49%, reflecting improved operational efficiency Current assets balance of $12.17 million as of December 31, 2025, including $9.40 million receivable in connection with the private placement of securities that closed on January 2, 2026. NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, no

    2/12/26 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Reports Fiscal 2026 First Quarter Financial Results and Operational Highlights, Delivering Record Revenue Growth

    Record quarterly revenue of $1.11 million, an increase of 32% sequentially and 28% year-over-year, driven by consumable cartridge sales and customer base expansion Gross profit margins increased 690 basis points year-over-year to 46.6%, reflecting improved operational efficiency and greater revenue percentage from higher margin cartridge sales NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal first quarter ended September 30, 2025. The fiscal 2026 first

    11/12/25 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

    Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in Mid-2026 KANSAS CITY, Kan., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended June 30, 2025, and provided recent highlights. Recent Highlights: On July 31, 2025, Cingulate submitted its NDA to the FDA for CTx-1301, a novel, extended-release tablet formulation

    8/19/25 8:45:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    $GRI
    $INBS
    $MARK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Minim Inc.

    SC 13D/A - MINIM, INC. (0001467761) (Subject)

    11/15/24 5:00:07 PM ET
    $MINM
    Telecommunications Equipment
    Utilities

    Amendment: SEC Form SC 13G/A filed by Cingulate Inc.

    SC 13G/A - Cingulate Inc. (0001862150) (Subject)

    11/14/24 7:21:05 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Intelligent Bio Solutions Inc.

    SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 7:16:17 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care